NCT07354321Not yet recruiting
Thrombo-inflammation in Acute Neurovascular Diseases: Definition of New Therapeutic Targets (TARGETS)
Thrombo-inflammation Des Maladies Neurovascualires aiguës : définition de Nouvelles Cibles thérapeutiques (TARGETS)
Source: ClinicalTrials.gov · Last updated 5 Feb 2026
Brief summary (registry, in English)
The objective of this observational study is to compare the relative concentrations of various thrombo-inflammatory markers at different follow-up time points in: * patients with or without delayed cerebral ischemia after subarachnoid hemorrhage, and * patients with or without rapid progression of necrotic volume after an ischemic stroke due to large- or medium-vessel occlusion in the anterior circulation. The main question this study aims to answer is: How do thrombo-inflammatory marker concentrations evolve over time and differ between patients? Researchers will compare patients with or without delayed cerebral ischemia after subarachnoid hemorrhage, as well as patients with or without rapid progression of necrotic volume following an ischemic stroke due to large- or medium-vessel occlusion in the anterior circulation, to determine whether there are differences in thrombo-inflammatory marker concentrations and in their evolution over time. Participants will undergo blood sampling at five different time points. In addition, participants will complete a Montreal Cognitive Assessment (MoCA) questionnaire during the 3-month follow-up visit.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 499 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- Feb 2026
- Primary completion date
- May 2032
- Lead sponsor
- François Delvoye
- Diseases
- Stroke
- NCT number
- NCT07354321
What you commit to
- Study type: Observational
- Planned participants: 499
- From Feb 2026 to the primary completion date, May 2032
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with secondary hemorrhagic transformation of an acute ischemic stroke
- Patients with acute ischemic stroke and NIHSS \> 5 without LVO or MeVO of the anterior circulation on imaging will be secondarily excluded. Perfusion imaging will not be performed as part of the research protocol. Excluded patients will be replaced.
Other
- Patients with pre-existing functional and/or cognitive disability (modified Rankin Scale, mRS \> 1)
- Patients under legal protection or guardianship
Who the study is looking for
- Patients aged 18 years or older
- Admitted within 8 hours of an acute ischemic stroke (AIS) due to large-vessel occlusion (LVO) or medium-vessel occlusion (MeVO) of the anterior circulation, with a NIHSS (National Institutes of Health Stroke Scale) score \> 5 (M1, M2, M3, A1, A2, A3, P1, P2)
- Or admitted within 36 hours of acute symptoms related to aneurysmal subarachnoid hemorrhage (SAH)
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.